Objective: We explored the impact of uncertain resection in lung cancer on overall survival and disease-free survival. Methods: We performed an exhaustive literature review of all studies comparing prognosis after resection according to the IASLC classification, from the PubMed, Cochrane, MEDLINE, and Google Scholar databases. Results: Overall, 68 original studies were included, of which 67 were retrospective and 1 was prospective, with 81 785 patients included over 46 years. R(un) reclassification was mostly caused by a lack of hilar or mediastinal node dissection, or because of metastasis in the highest node. R(un) is a strong factor for higher recurrence and mortality, while its effects seem limited in early stages. Carcinoma in situ at bronchial margin resection (CIS BRM) does not show an effect on survival, while positive pleural cytology (Cy+) and positive highest mediastinal lymph node (HMLN+) appear to be highly predictive of recurrence and death. Discussion: The R(un) classification of the IASLC appears highly relevant, especially in locally advanced stages IIb-IIIA, and helps to discriminate patients with poor prognosis despite being classified as R0 in the UICC classification. Conclusions: The use of this more precise classification would allow for better stratification of recurrence risk and more effective use of adjuvant therapies. Cy+ patients should receive adjuvant chemotherapy, while CIS BRM patients could likely benefit from endoscopic surveillance to detect local recurrences. HMLN+ patients should be considered at high risk of recurrence, and adjuvant radio-chemotherapy should be considered.
Background: Intraoperative fluid management remains a debated component of Enhanced Recovery After Surgery (ERAS) pathways in thoracic surgery, with current guidelines recommending intraoperative infusion rates of 2–6 mL/kg/h despite limited high-quality evidence. We assessed whether the intraoperative fluid infusion rate was associated with prolonged length of stay (LOS) after major pulmonary resection. Methods: We retrospectively reviewed 540 consecutive patients undergoing lobectomy, bi-lobectomy, or segmentectomy within a structured ERAS pathway, stratified by intraoperative infusion rate: G1 8 mL/kg/h ( n= 136). Multivariable logistic regression was performed to identify risk factors for prolonged LOS (>3 nights), before we conducted a generalised (multinomial) propensity score matching on four covariates (FEV1, blood loss, operating time, open surgical approach), yielding 59 matched triplets (177 patients). Results: Prolonged LOS occurred in 206 patients (38.1%) and was independently associated with high intraoperative infusion rate (OR 2.86 [1.70–4.81]; p< 0.001). Propensity score matching confirmed a statistically significant association between prolonged LOS and infusion rate with 62.7% of G3 patients experiencing prolonged LOS compared to 42.4% in G2 and 39.0% in G1 ( p= 0.020). Conclusions: Within a structured ERAS programme, high intraoperative fluid infusion rates (>8 mL/kg/h) were independently associated with prolonged length of stay after major pulmonary resection, in both multivariable and propensity-matched analyses. These findings suggest that high fluid infusion rates may be associated with longer hospital stay. Future efforts should prioritise prospective evaluation of individualised fluid strategies.
Objective: We aimed to explore the relevance of uncertain resection in lung cancer. Methods: We performed an exhaustive literature review of all studies comparing prognosis after resection according to IASLC classification. Results: Systematic review led to select 68 original studies included in this review. R(un) reclassification was mostly caused by a lack of hilar or mediastinal node dissection, or because of metasta-sis in the highest node. R(un) is a strong factor for higher recurrence and mortality, while its effects seem limited in early stages. Carcinoma in situ at bronchial margin resection (CIS BRM) does not show effect on survival, while positive pleural cytology (Cy+) and positive highest mediastinal lymph node (HMLN+) appear to be highly pre-dictive of recurrence and death. Conclusion: The R(un) classification of the IASLC 2005 appears highly relevant, espe-cially in locally advanced stages IIb-IIIA, and helps to discriminate patients with poor prognosis despite being classified as R0 according to UICC classification. The use of this more precise classification would allow for better stratification of recurrence risk and more effective use of adjuvant therapies. Cy+ patients should receive adjuvant chemotherapy, while CIS BRM patients could likely benefit from endoscopic surveil-lance to detect local recurrences. HMLN+ patients should be considered at high risk of recurrence, and adjuvant radiochemotherapy should be considered.